Food and Drug Administration Grants Two New Label Changes to TIROSINT®-SOL (LEVOTHYROXINE SODIUM) Oral Solution

New FDA-approved label updates offer patients more flexible administration PARSIPPANY, N.J., December 4, 2023 — The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a unique formulation of levothyroxine (LT4) for the treatment of hypothyroidism. The first regards the use of Tirosint-SOL in Read More »

Pro golfer Azahara Muñoz featured on The Balancing Act® airing on Lifetime TV®

Azahara Discusses Battle with Hashimoto’s Disease and Success with Tirosint®-SOL(levothyroxine sodium) oral solution  PARSIPPANY, N.J. Professional golfer Azahara Muñoz and endocrinologist Dr. Kenilia Ventura will be featured on The Balancing Act® , a morning show produced by BrandStar® and airing on Lifetime TV®. The segment, hosted by Montel Williams and Olga Villaverde, will be broadcast Read More »

New Guidelines Cite Oral Levothyroxine Solution as an Option for Treating Congenital Hypothyroidism (CH)

Guidance Supports Use of Tirosint®-SOL In Pediatric Population Parsippany, N.J. The American Academy of Pediatrics (AAP), the Pediatric Endocrine Society (PES) and the American Thyroid Association (ATA) have published new guidelines for the treatment of congenital hypothyroidism (CH). For the first time, these leading medical societies cite levothyroxine oral solution as an option for managing Read More »